Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Kalytera Therapeutics Inc. (V:KLY)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for KLY within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Dec 20, 2019 18:57 ET
Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has not paid the principal (in the amount of C$453,000) and interest (in the amount of C$19,323.96) owing on its 9% secured...
Read full article
Dec 16, 2019 08:00 ET
Kalytera Announces Extension of Maturity Date of Promissory Note
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that, in accordance with the previously announced agreement between the Company and the former shareholders of the Company’s subsidiary,...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.53
--
--
Price to Sales - TTM
--
13.78
8.90
Price to Book - most recent quarter
3.31
3.40
2.31
Price to Cash Flow per share - TTM
--
--
9.87
Price to Free Cash Flow per share - TTM
--
1.27
17.21
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 196900
Dec 31, 196900
Dec 31, 196900
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Kalytera Therapeutics Inc, formerly Santa Maria Petroleum Inc. is a Canada-based company, engaged in the development of cannabinoid (CBD) therapeutics. The Company is developing CBD formulations and prodrugs to target specific disease sites within the body. The Company's development programs include Bone Fracture Healing, Osteogenesis Imperfecta, Osteoporosis and Osteoporosis in Prader-Willi syndrome (PWS). The Company is focused on the development of KAL436/9, which is a synthetic derivative of CBD that has been structurally modified to develop solubility in water to improve potency. Its KAL671 is a synthetic fatty acid amide and an endocannabinoid-like molecule that may restore bone in persons suffering from osteoporosis. The Company's researchers are exploring the ability for KAL671 to prevent bone loss in mice with genetic mutations designed to mimic aspects of PWS.

See business summary

Twitter

Search (past week) for $KLY.CA KLY.V